- Home
- IKNA vs BAFN Comparison
IKNA vs BAFN Comparison
Compare IKNA & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- BAFN
- Stock Information
- Founded
- IKNA 2016
- BAFN 1999
- Country
- IKNA United States
- BAFN United States
- Employees
- IKNA N/A
- BAFN N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- BAFN Savings Institutions
- Sector
- IKNA Health Care
- BAFN Finance
- Exchange
- IKNA Nasdaq
- BAFN Nasdaq
- Market Cap
- IKNA 61.8M
- BAFN 65.2M
- IPO Year
- IKNA 2021
- BAFN N/A
- Fundamental
- Price
- IKNA $1.36
- BAFN $13.85
- Analyst Decision
- IKNA Strong Buy
- BAFN
- Analyst Count
- IKNA 1
- BAFN 0
- Target Price
- IKNA $4.00
- BAFN N/A
- AVG Volume (30 Days)
- IKNA 95.6K
- BAFN 5.5K
- Earning Date
- IKNA 08-07-2025
- BAFN 07-24-2025
- Dividend Yield
- IKNA N/A
- BAFN 2.22%
- EPS Growth
- IKNA N/A
- BAFN 116.26
- EPS
- IKNA N/A
- BAFN 2.37
- Revenue
- IKNA N/A
- BAFN $80,167,000.00
- Revenue This Year
- IKNA N/A
- BAFN N/A
- Revenue Next Year
- IKNA N/A
- BAFN N/A
- P/E Ratio
- IKNA N/A
- BAFN $5.84
- Revenue Growth
- IKNA N/A
- BAFN 2.60
- 52 Week Low
- IKNA $0.97
- BAFN $11.10
- 52 Week High
- IKNA $1.94
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- IKNA 56.43
- BAFN 37.55
- Support Level
- IKNA $1.10
- BAFN $13.55
- Resistance Level
- IKNA $1.46
- BAFN $15.30
- Average True Range (ATR)
- IKNA 0.07
- BAFN 0.77
- MACD
- IKNA -0.00
- BAFN -0.06
- Stochastic Oscillator
- IKNA 57.58
- BAFN 23.27
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.